Colchicine Plus Phenolic Monoterpenes to Treat COVID-19
Status:
Completed
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
In this randomized controlled clinical trial, defined cases of COVID-19 with mild, moderate,
or severe pneumonia (according to the NIH guideline) were treated with conventional treatment
regimens (controls) as well as in combination with oral administration of colchicine plus
herbal phenolic monoterpene fractions (intervention arm). After randomization, each group
received the mentioned treatments and were evaluated for different variables including
mortality, hospitalization duration, intensive care unit (ICU) administration ratios as well
as laboratory variables such as leukocytes and lymphocytes count. The follow-up period
considered as 2 weeks after discharge. The mentioned variables were assessed as before and
after receiving the treatment in each group as well as intergroup analysis for comparing both
baseline and final values.